Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ewing Sarcoma - Overview
Ewing Sarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ewing Sarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ewing Sarcoma - Companies Involved in Therapeutics Development
Ewing Sarcoma - Drug Profiles
Ewing Sarcoma - Dormant Projects
Ewing Sarcoma - Discontinued Products
Ewing Sarcoma - Product Development Milestones
Featured News & Press Releases
Sep 28, 2022: Rakovi Therapeutics announces upcoming scientific conference presentations
May 11, 2022: Rakovi Therapeutics presents preclinical data on its novel kt-3000 series at the 2022 AACR Special Conference on Sarcomas
Apr 23, 2022: Nektar and collaborators present preclinical data on NKTR-255, a novel IL-15 receptor agonist, in combition with CAR cell therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Mar 30, 2022: Rakovi Therapeutics to present abstract at the 2022 AACR special conference - Sarcomas
Nov 01, 2021: Inhibrx announces participation in upcoming scientific and investor conferences
May 10, 2021: TYME announces abstract selected for publication at the 2021 American Society of Clinical Oncology Annual Meeting
Aug 24, 2020: New treatment developed by CHOP shows success in high-risk solid tumors
Aug 11, 2020: TYME announces outcome of interim futility review for HopES sarcoma phase II study
May 28, 2020: TYME announces abstracts selected for publication at the 2020 American Society of Clinical Oncology Annual Meeting
May 14, 2020: Cellectar granted composition of matter and use patent in Europe for CLR 131
Jan 16, 2020: TYME and The Joseph Ahmed Foundation announce first patient dosed in phase II (HopES) trial evaluating the potential benefits of oral SM-88 for patients with high-risk sarcomas
Aug 20, 2019: noValent Pharmaceuticals announces issuance of United States patent for application of targeted polymerized noparticles in cancer treatment
Aug 14, 2019: CLR 131 advances to second malignt brain tumor cohort of ongoing pediatric phase 1 study
May 23, 2019: TYME and The Joseph Ahmed Foundation announce initiation of the HopES Phase II trial evaluating the potential benefits of SM-88 for patients with high-risk Sarcomas
Mar 04, 2019: Gradalis announces medical leadership team promotion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Ewing Sarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Ewing Sarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ewing Sarcoma - Dormant Projects, 2022
Ewing Sarcoma - Dormant Projects, 2022 (Contd..1)
Ewing Sarcoma - Discontinued Products, 2022